Drug Profile

Hypidone hydrochloride - Shanghai Synergy Pharmaceutical Sciences

Latest Information Update: 26 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Synergy Pharmaceutical Sciences
Class Antidepressants; Piperidines; Pyridines
Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Jul 2022 No development reported - Phase-II for Major depressive disorder in China (PO)
15 Jan 2021 Zhejiang Huahai Pharmaceutical completes a phase I trial for Major depressive disorder (In volunteers) in China (NCT04598607)
22 Oct 2020 Shanghai Synergy Pharmaceutical Sciences plans a phase I trial in Major depressive disorder (In volunteers) in China in October 2020 (PO, Tablet) (NCT04598607)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com